Quality of Life in Patients with Pancreatic Cancer
Abstract
Pancreatic cancer is a rapidly fatal disease with palliation often serving as the main goal of treatment. The end of life is often marked by severe symptoms and poor quality of life (QoL). Several studies presented at the 2012 ASCO Gastrointestinal Cancers Symposium addressed the importance of symptom identification and management for patients with pancreatic cancer: 1) a study evaluating the correlation between patient-reported symptoms, disease burden and treatment duration in patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy (Abstract #370); 2) a Japanese study found that patients without worsening of pain or sleep symptoms at one month of chemotherapy had higher frequency of disease control (Abstract #195); and 3) a study showed that fear of cancer recurrence is a substantial problem following resection and should be targeted (Abstract #289). The authors summarize the findings and discuss the importance of QoL in these patients. The results of these studies may facilitate in identifying symptom changes as predictive markers, and improving care and QoL for patients with this devastating disease.
Downloads
References
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society 2012.
Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. [PMID 9196156]
Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP 2007; 8: 240-253. [PMID 17356251]
Gupta D, Lis CG, Grutsch JF. The European organization for research and treatment of cancer quality of life questionnaire: implications for prognosis in pancreatic cancer. Int J Gastrointest Cancer 2006; 37: 65-73. [PMID 17827524]
Lis CG, Gupta D, Grutsch JF. Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer. Int J Gastrointest Cancer 2006; 37: 35-44. [PMID 17290079]
Bernhard J, Dietrich D, Glimelius B et al. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 2010; 103: 1318-1324. [PMID 20877359]
Wang XS, Fogelman DR, Shi Q et al. Patient-reported symptoms from patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy. J Clin Oncol 2012; 30: Suppl 4; abstr 370.
Kuwahara A, Mitsunaga S, Ohno I et al. Symptom change that predict disease control by systemic chemotherapy in patients with advanced pancreatic cancer. J Clin Oncol 2012; 30: suppl 4; abstr 195.
Romanus D, Kindler HL, Archer L et al. Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J Pain Symptom Manage 2012; 43: 205-217. [PMID 22104618]
Petzel MQB, Parker NH, Valentine AD et al. Fear of cancer recurrence and quality of life among survivors of pancreatic and periampullary neoplasms. J Clin Oncol 2012; 30: Suppl 4; Abstr 289.
Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (>/=5 years) cancer survivors-a systematic review of quantitative studies. Psychooncology 2012. [PMID 22232030]
Copyright (c) 2014 Valerie Lee, Haiying Cheng, Guangyuan Li, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.